Subscribe to Search results

Dr Lane's view was that "the risks of transmission of HIV were such that heat treatment should be employed even if it turned out to be a temporary expedient."

Published on:

There were fears that the Factor 9 concentrate in particular - but also Factor 8 - might give rise to a greater risk of thrombosis from the heat-treated product, although research facilities were limited, scientific staff were few, and BPL suffered from a lack of viral containment equipment.

Published on:

Dr Richard Lane recorded that no work was done by BPL during 1981 to research heat treatment.

Published on:

BPL planned to apply dry heat treatment to all the Factor 8 produced at BPL because it was shown that heat treatment appeared to inactivate the HTLV-3 virus which by then had been identified as the cause of AIDS.

Published on:

According to Dr Lane, a "requirement for central funding for research and development was a continuous theme in 1981."

Published on:

Dr Lane complained that the "Department of Health policy was that Regional Health Authorities were to all intents and purposes responsible for allocation of budgets, and the Department of Health would not intervene in the exercise of their discretion."

Published on:

Dr Lane's account of 1981 was one of his battles to secure a commitment from the government to redevelop BPL, and to fund the improvements necessary following an adverse Medicines' Inspectorate report.

Published on:

Dr James Smith proposed to Dr Lane some first outline proposals for programmes to research tackling the transmission of viruses by coagulation factor concentrates. This proposal, according to Dr Lane, marked "the start of a move towards a viral inactivation programme."

Published on:

It was apparent that there was some resistance by some clinicians to the use of heat-treated product.

Published on:

Professor Garrott Allen wrote to Dr William Maycock stating: "As you know" Cutter's Konyne was "extraordinarily hazardous".

Published on:

Dr Maycock stated: "DHSS, in order to be able to carry with confidence its responsibility for providing the transfusion service in England and Wales, should consider fostering the development of a central transfusion research laboratory."

Published on:

Capital funding was the preserve of central government, which considered that so far as the laboratory at BPL was concerned "expenditure on up-grading should be reviewed and minimised pending a decision on the laboratory's future."

Published on:

Dr James Smith wrote: "The significance of a product demonstrably free of hepatitis risk cannot be ignored and it is essential that BPL/PFL be well placed to take advantage of such developments."

Published on:

Dr Lane reported to the Scientific and Technical Committee of the Central Blood Laboratories Authority during the next month that "a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission, was an appropriate case for central funding."

Published on:

Dr Lane recorded that he proposed to the CBLA Scientific and Technical Committee in the spring of 1981 that a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission was an appropriate project for central funding.

Published on:

A paper was produced by the Research and Development department of BPL, which noted that heating albumin products for such a period in the presence of a stabiliser had a "good record in the elimination of hepatitis virus infectivity" and that "If similar stabilisers can be established for coagulation factor products then heat inactivation will become the treatment of choice."

Published on:

A number of other possibilities for reducing the risk of hepatitis were canvassed by BPL 1981.

Published on:

Dr Smith visited PFC in Scotland and discussed research and development in respect of coagulation factors, and put forward to Dr Lane a "Proposal to Develop a 'Hepatitis-Safe' Factor VIII Concentrate".

Published on:

The draft proof of evidence of Dr Richard Lane expressed that "NANBH causes increasing concern, less on account of its acute effects (although deaths have been reported) than because of its association with chronic active hepatitis in later life", and that AIDS was "not yet proven to be of viral origin, but this is strongly presumed".

Published on:

Dr Smith proposed to make a special preparation of Factor 8 which would be subjected to dry heat (8CRV).

Published on: